The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Deal Review: June 29, 2009

B&W_BigNickelThis week’s Monday Deal Review has a full set of equity deals from shelf to launch to close, one new U.S. registration and one deregistration to match, and some ideas for what to do with your debt (!), all

Ready, Set, Go, Close….

Oncogenex (NASDAQ: OGXI) put up a new shelf registration statement, although they said they are not planning to use it to fund the OGX-011 Phase 3 trials that generated so much excitement this week.

DiagnoCure (TSX: CUR) launched a Canadian offering of common shares (the preliminary prospectus is on SEDAR) through a syndicate of agents co-led by National Bank Financial Inc. and Bloom Burton & Co. and including Desjardins Securities Inc.

Æterna Zentaris, Inc. (TSX: AEZ, NASDAQ: AEZS) closed the $10 million offering it launched last week.

You Put Your Helix In, You Take Your Neovasc Out…

Helix BioPharma Corp. (TSX, FSE: HBP), following its registration with the SEC in March, has commenced trading in the U.S. on the OTCQX International Market under the ticker symbol HXBPF.

Neovasc Inc. (TSXV: NVC), which had filed a 20-F registration statement last June, has decided not to pursue a U.S. listing.

Will Trade Debt for…

PharmaGap Inc. (TSX-V: GAP), no novice when it comes to debt-for-shares deals, announced that it is converting $215,201 owed to the National Research Council of Canada, issuing  1,434,676 common shares to NRC at $0.15 per common share.  NRC will hold a total of 3.2% of PharmaGap’s common shares.

Labopharm Inc. (TSX: DDS; NASDAQ: DDSSamended its debt facility agreement with Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), extending payments to July 1, 2010 from July 1, 2009, and maturity to June 1, 2012 from December 1, 2011. Labopharm is promising not to draw down the remaining US$5 million of the US$25 million credit facility; but is picking up $2.6 million from the National Bank of Canada.

Bookmark and Share

About these ads

3 responses to “Monday Deal Review: June 29, 2009

  1. Pingback: Monday Deal Review: July 20, 2009 « The Cross-Border Biotech Blog

  2. Pingback: Monday Deal Review: July 27, 2009 « The Cross-Border Biotech Blog

  3. Pingback: Monday Biotech Deal Review: October 25, 2009 « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 129 other followers